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Background: Chronic gastritis (CG), a poorly understood entity, is a very common disease of the digestive tract
and is difficult to cure. Chronic non-atrophic gastritis (CNG) is the most common type of CG. Even if treated with
current standard chemotherapy, some patients will not be freed from this confusing disease. Many studies have
shown traditional Chinese medicine (TCM) is more effective compared to chemotherapy in the treatment of
chronic gastritis and no serious side effects have been identified. However, the studies that have been carried out were
not scientifically rigorous trials. Our aim is to design a high-quality trial for a new TCM drug, the Jian-Wei-Qu-Tong Pills
(JWQTP), to investigate the efficacy and safety of this new drug in treating chronic non-atrophic gastritis patients with
spleen and stomach qi deficiency with damp-heat stasis syndrome (SSQDDSS).
Methods/Design: This is a phase II, multicenter, parallel-group, double-blind, randomized and placebo-controlled trial.
A total of 240 participants will be assigned to a high-dose group, a low-dose group or a placebo control group with a
1:1:1 ratio at five sites. Then, one dose (six 1-g pills), with a variable ratio between real drug and dummy drug according
to the intervention protocol, will be taken three times a day before each meal for 8 weeks. The primary outcome
is the eradication rate of epigastric pain. The secondary outcome includes the changes of endoscopic examination,
histopathological examination, traditional Chinese medicine symptom scores and patient-reported outcome
instrument scores for chronic gastrointestinal diseases and the eradication rate of Helicobacter pylori (HP).
Discussion: Many CNG patients suffer from frequent, recurrent bouts of dyspeptic symptoms. This is the first
clinical trial to evaluate the safety and efficacy of JWQTP in treating CNG with SSQDDSS in a multicenter,
parallel-group, double-blind, randomized and placebo-controlled manner. This trial may not only provide evidence
for a phase III clinical trial, but also a vision of an alternative option for CNG treatment.
Trial registration: The registration number, ChiCTR-TRC-14004088, was assigned by the Chinese Clinical Trial
Registry on 7 January 2014.
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Chronic gastritis (CG), which is induced by various
causes, is a very common disease of the digestive tract
and is an inflammatory condition of the gastric mucosa
[1]. Among the possible etiological factors, Helicobacter
pylori (HP) infection is the most common cause of
chronic gastritis worldwide, with the remaining cases
arising due to smoking, drinking, duodenal juice reflux,
food allergies, heredity, drug-induced injuries, immunity,
Crohn’s disease, other infectious pathogens or radiation
[2-4]. Chronic gastritis can be categorized into non-
atrophic gastritis, atrophic gastritis and special types of
gastritis, according to the Consensus on Chronic Gastri-
tis in China (Shanghai 2012) [5]. Chronic non-atrophic
gastritis (CNG) is characterized by the infiltration of
chronic inflammatory cells and the absence of atrophy
in the mucosal layer. Although the prevalence rate in
the general population remains unclear, a national multi-
center cross-sectional study led by the Digestive Endos-
copy Branch of Chinese Medical Association showed
that 49.3% of the investigated patients (4,389/8,892) with
upper gastrointestinal symptoms who underwent diag-
nostic upper endoscopy for the evaluation of gastrointes-
tinal symptoms from 33 centers had CNG, which was
the most common [6]. Symptomatic patients with CNG
may manifest nonspecific dyspeptic symptoms, such as
epigastric discomfort, distention, belching, acid regurgi-
tation, nausea, vomiting, loss of appetite and anergy,
while some patients have no symptoms. The pathogen-
esis of chronic gastritis is complex and difficult to cure.
The focused Western medical treatment of chronic gas-
tritis involves the eradication of HP, antacids, prokinetics
and mucosal-protective agents to ameliorate the symp-
toms [5,6]. However, even if treated with the above stand-
ard therapies, some patients will not be freed from this
disease. Traditional Chinese medicine (TCM), which has
recently become a research focus in particular contexts,
can broaden the therapeutic approaches to CNG [7-11].
Traditional Chinese medicine, which has been estab-
lished for over 5,000 years, has been widely used to treat
diseases, including CNG. Based on its clinical manifesta-
tions, CNG can be categorized as Weiwantong (stomach
ache), Piman (abdominal distention) or Caoza (gastritis
discomfort) in the field of Chinese medicine (CM); TCM
divides CNG into five common single syndrome pat-
terns: (1) spleen (Pi) and stomach (Wei) deficiency syn-
drome (including spleen and stomach qi deficiency
syndrome and spleen and stomach deficiency-cold syn-
drome); (2) incoordination between liver (Gan) and
stomach syndrome (including liver qi invading stom-
ach syndrome and stagnant heat in liver and stomach
syndrome); (3) stomach yin deficiency syndrome; (4)
spleen and stomach dampness-heat syndrome; and (5)
blood stasis in stomach collaterals syndrome [3]. Theconcurrence of two or more individual patterns can be
considered a complicated pattern and is common in
clinical practice [12]. The TCM treatment relies on
correct syndrome differentiation (SD), by which accu-
mulating symptoms and signs are identified through
inspection, auscultation and olfaction, inquiring, and
palpation to uncover the ongoing abnormal condition.
Therefore, TCM agents operate through other path-
ways that may be helpful for patients who are nonre-
sponsive to standard therapies.
A new TCM drug, the Jian-Wei-Qu-Tong Pills (JWQTP),
is currently being manufactured by Anbang Pharmaceutical
Limited by Share Ltd, Hunan, China. The prescription for
this pill is based on both TCM theory and the clinical ex-
perience and herbal studies of prominent TCM doctors on
the treatment of CNG. Components of the pill include:
Radix Pseudostellariae, Rhizoma Coptidis, Rhizoma Atracty-
lodis Macrocephalae, Semen Coicis, Rhizoma Pinelliae Pre-
parata, Radix Notoginseng, Pollen Typhae, Herba Taraxaci
Mongolici, Rhizoma Corydalis Yanhusuo, Cortex Magnoliae
Officinalis and Radix Glycyrrhizae preparata. All of these
herbs have been approved by the China Food and Drug Ad-
ministration (CFDA). This pill can strengthen the spleen,
supplement qi, clear heat, remove dampness and promote
blood circulation to remove blood stasis and relieve pain.
Thus, it can be used for spleen and stomach qi deficiency
with damp-heat stasis syndrome (SSQDDSS) in CNG pa-
tients. Preclinical pharmacologic experiments, which have
not been published, show that JWQTP can neutralize gastric
acid; reduce gastric acidity, pepsin activity, free mucus, gas-
trin, TNF-α and IL-2; elevate the level of IL-4; create balance
between the Th1 and Th2 cells; and then reduce inflamma-
tion in rats’ gastric mucosa to protect against CG. Further-
more, this treatment was able to eradicate HP in the gastric
mucosa of mice to some degree, provide an analgesic effect
and play a regulatory role on gastric emptying. Additionally,
there was no evidence to show an adverse or toxic effect in
toxicological studies.
The specific objectives of this trial included evaluating
the efficacy and safety of JWQTP in treating CNG pa-
tients with SSQDDSS, including any dose-effect relation-
ship, and providing evidence for a Phase III clinical
program.
Methods/Design
This current study is a phase II, multicenter, parallel-
group, double-blind, randomized and placebo-controlled
trial. The study will be conducted in compliance with the
Declaration of Helsinki, Good Clinical Practice (GCP)
Guidelines [13] and the requirements of clinical trials by
the Drug Administration Law of the People's Republic of
China, and will strictly observe all laws governing new
TCM drugs. The study was approved by the CFDA
(Approval No. 2012 L02382), and the protocol and
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West China Hospital of Sichuan University Clinical
Trials and Biomedical Ethics Committee (No. TCM-
2013-06). In addition, it was registered in the Chinese
Clinical Trial Registry (ChiCTR-TRC-14004088). We
will recruit subjects by advertising on the hospital’s no-
tice board or through recommendations in the outpatient
clinic. All patients must provide written informed consent.
The trial is financially supported by Anbang Pharmaceut-
ical Limited by Share Ltd, Hunan, China, which did not
contribute to the study design, data collection, data man-
agement, analysis, interpretation of data or decision to
submit the report for publication, except for the provision
of all test drugs. Each trial center has a project manager
who is responsible for the quality of research. Standard
training will be required for all investigators before the
trial. An independent trial inspector will pay regular visits
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Figure 1 Study flow chart.supervise the research to make sure it complies with the
protocol throughout the trial. Figure 1 shows the flow
chart of this trial.
Patient population and setting
A total of 240 patients will be enrolled at the following
five sites: (1) West China Hospital of Sichuan University,
(2) the first Affiliated Hospital of Guiyang College of
Traditional Chinese medicine, (3) the first Affiliated
Hospital of Hunan University of Chinese Medicine, (4)
the first Affiliated Hospital of Guangxi University of
Chinese Medicine and (5) the Ruikang Hospital affiliated
to Guangxi University of Chinese Medicine. In other
words, 48 patients will be recruited at each hospital.
Randomization
For randomization, the participants will be assigned into a
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method, with stratification by center. The randomization
sequence will be created at the West China Hospital of
Sichuan using SAS 9.2 software to determine the ap-
propriate segment. Two copies of the randomization
list will be kept in safe places - one by the West China
Hospital of Sichuan University drug clinical trial agency
and one by the sponsor of this study - during the study
period. Each patient will receive a unique randomized test
number corresponding to the specified drug, according to
the group allocation. An emergency envelope has been
prepared for each test number and is to be opened for
treatment allocation only due to medical emergency.Diagnosis in Western medicine
Referring to consensus on chronic gastritis in China
(Shanghai, 2012) [5], consensus on the diagnosis and
treatment of chronic gastritis by integrative medicine
(Tianjin 2011) [14], Practice of Internal Medicine (2009,
Version 13) [15] and endoscopic classification and trial
standards on treatment of chronic gastritis (Dalian,
2003) [16], which is the diagnostic criteria for CNG in
Western medicine, are listed as follows:Clinical manifestations
Most symptomatic patients with CNG have nonspecific
dyspepsia, such as epigastric pain, distention, belching,
acid regurgitation, nausea, vomiting and loss of appetite.Table 1 Endoscopic characteristics, grading and scoring
Endoscopic appearance Endoscopic characteristics
Red plaques Apparent rubefaction in the normal gastric
mucosa
Erosion Flattened or varioliform erosions: superficial
mucosa is ruptured, along with flat or ridge
erosion in the surrounding area
Hemorrhage Hemorrhage in the mucosa: flattened
hemorrhagic spots/plaques with bright
red or dark red, together or not witherrhysi
Bile reflux Olive green gastric juice; bile flow back into
stomach because of opened pyloric orificePhysical signs
There is no finding in most patients’ physical examina-
tions, although some patients may feel slight epigastric
pain or discomfort when pressed on the upper abdomen.
Only a tiny minority of these patients are gaunt or
anemic.
Endoscopic and histopathological diagnosis
Because there is no specific symptom, the diagnosis of
CNG relies primarily on endoscopic and histopatho-
logical examinations, particularly the latter. The funda-
mental appearance of non-atrophic gastritis shows red
plaques (punctuates, patches and striae), coarse and un-
even mucosa, hemorrhagic spots/plaques, edematous mu-
cosa, and exudates at endoscopy. No atrophic changes,
intestinal metaplasia, dysplasia or pseudopyloric gland
metaplasia are found in the histopathological examination
of the gastric mucosa. Table 1 shows that the red plaques,
erosion, hemorrhage and bile reflux are further graded
into four grades at endoscopy, as chronic inflammation
and active chronic inflammation in the histopathological
examination observed are in Table 2.
Chinese medicine diagnostic criteria of the spleen and
stomach qi deficiency with damp-heat stasis syndrome
In acknowledgement of the consensus on diagnosis and
treatment of chronic superficial gastritis with TCM
(Shenzhen, 2009, Digestive Disease Branch of China
Association for Traditional Chinese Medicine) [17],Grading system Score
None 0
Grade I: sporadic or interrupted linear type 1
Grade II: intensive plaques or linear series type 2
Grade III: extensive fusion 3
d
None 0
Grade I: sporadic 1
Grade II: local, multiple but no more than five 2
Grade III: extensive, multiple and no less than six 3
s
None 0
Grade I: local 1
Grade II: multiple sites 2
Grade III: widespread 3
None 0
Grade I: yellowish or flavo-green mucinous lake 1
Grade II: lies between grade I and grade III 2
Grade III: massive yellow bile flow back into
stomach, yellow mucus adhere to gastric mucosa
3
Table 2 Histopathological changes, grading and scoringa
Histopathological changes Grading system Score
Chronic inflammation Normal or number of mononuclear cells less than 5/high power field 0
+ (mild): Some chronic inflammatory cells are localized in the superficial
layer of the mucosa, but not more than 1/3 of the depth of the mucosa;
1
++ (moderate): A more dense accumulation of chronic inflammatory
cells, but not exceeding 2/3 of the depth of the mucosa
2
+++ (severe): A dense accumulation of chronic inflammatory cells
occupying the whole depth of the mucosa
3
Active chronic inflammation Normal 0
+ (mile): Few neutrophils in the lamina propria of the mucosa 1
++ (moderate): More neutrophils in the mucosal layer and between
superficial epithelial cells, pit epithelial cells and glandular epithelial cells.
2
+++ (severe): A more dense infiltration of neutrophils, or abscess on
pits can be seen in addition to what is seen in moderate activity.
3
aTwo to five biopsy specimens reaching musculature in the mucosa will be taken from gastric antral, gastric angle or suspected focal lesions of sufficient size. For
the specimens taken at the first and sixth visits, the regions should be chosen consistently as possible as it can.
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dards • the standards of diagnosis and efficacy of
TCM syndromes [18], and the Guidelines For Clinical
Research On Chinese New Herbal Medicines (Trial
Implementation) [19], the CM diagnostic criteria of
SSQDDSS in CNG patients are listed and include the
following:
1. Primary symptom: epigastric pain.
2. Secondary symptoms: weakness and lassitude, dry
mouth/bitter taste in mouth, loss of appetite,
distention and fullness, loose stool or belching.
3. Tongue presentations: pale tongue, dark red
tongue with ecchymosis or petechiae or enlarged
and teeth-printed tongue.
4. Tongue coating: yellow or yellowish greasy coating.
5. Pulse presentations: thread and weak pulse or
stringy pulse.
A diagnosis of SSQDDSS should include the primary
symptom, the first two secondary symptoms and more
than one of the remaining four secondary symptoms,




1. Diagnosis of CNG according to Western medicine
(moderate or severe level of chronic inflammation
and/or active inflammation).
2. Diagnosis of spleen and stomach qi deficiency with
damp-heat stasis syndrome, according to TCM
syndrome differentiation.




1. History of gastric surgery.
2. Combined gastric ulcer, duodenal ulcer, special types
of gastritis or gastrointestinal hemorrhage.
3. Histopathological examination showing atrophic
changes, intestinal metaplasia, dysplasia or
suspected malignant changes in the gastric
mucosa.
4. Serious comorbidities of heart, lung, liver, kidney or
blood system (such as cardiac function above grade
II, alanine aminotransferase (ALT) and/or aspartate
aminotransferase (AST) greater than 1.5 times the
upper limit of normal, creatinine (Cr) greater than
the upper limit of normal and so on) or having a
life-threatening illness (for example, tumor or
AIDS).
5. Positive fecal occult blood test.
6. Having received TCM or Western medicines to treat
CNG in the last 2 weeks.
7. Psychiatric disorders or a history of alcohol or drug
abuse.
8. Female patients preparing for a baby, pregnant or
lactating.
9. Allergic to the trial pills.
10. Currently participating or enrolled in another drug
trial over the last three months.
11. Unclear TCM diagnosis of syndrome differentiation
or too complicated SDs in TCM.
12. Having been judged inappropriate to participate in
the trial by investigators.




2. The trial drug is taken at doses <80% or >120% of
the requirement, or is not taken as directed.
3. Patients do not cooperate or cannot complete follow-up.
Withdrawal criteria
Withdrawal criteria include:
1. Intolerance to worsening conditions.
2. Quitting voluntarily.
3. Having manifestations of hemorrhage of the
digestive tract, such as melena or hematemesis
during the study.
4. Experiencing anaphylaxis following the trial drug’s
administration.
5. Adverse medical events occurring during the study,
such as severe liver function damage, malignant
tumors in other system, and accidental pregnancy or
other reasons, as judged by the investigators, that
might make the patient unlikely to complete the
study.
Suspending early or terminating the entire study
The study may be suspended early or terminated in the
event of the following:
1. Serious adverse event (SAE) caused by the trial
drugs.
2. The effect of the test drug is poor or even
completely ineffective.
3. Discovery of a blunder in the protocol or of a
significant deviation between the protocol and actual
practice
4. The decision to terminate the study being made by
the pharmaceutical supervisory and administrative
department or by the sponsors, for any reason.
Concomitant treatments and forbidden drugs
Subjects will be permitted to continue concomitant treat-
ment for comorbidities, such as hypertension, chronic
bronchitis, stroke or skin disease, which will not affect the
trial’s final results. However, they are forbidden to take
any CM or Western medicine related to CNG, such as
prokinetics, cholinergic agents, H2-receptor antagonists,
proton pump inhibitors, mucosal-protective agents or an-
tibiotics for the eradication of HP. Aspirin, nonsteroidal
anti-inflammatory drugs, sedative hypnotics, antidepres-
sants and opioids should be used sparingly. Each con-
comitant treatment should be documented strictly in the
CRF, and once a subject is found to be taking forbidden
drugs, he/she will be withdrawn from this study.Test drugs and blinding
The JWQTP and the dummy JWQTP will be manufac-
tured by Anbang pharmaceutical Limited by Share Ltd,
Hunan, China, with the approval of the CFDA for clin-
ical studies only (Approval No. 2012 L02382). Of note,
the dummy JWQTP is not exactly the same as the test
pill in color and smell. To make a blind test possible, all
of the drugs are concealed in unified, sealed and opaque
packages with the same labels that contain the drug
name, the approval number of the pill, functions, usage,
dosage, storage conditions, expiration dates for use and
the manufacturer’s name. The drugs are administered by
an independent clinical assistant in each center, who
takes responsibility for the drug’s distribution, storage
and return. Any members who have access to the drug
will not participate in case observations or efficacy eval-
uations. Each package contains one dose (six 1-g pills)
with a variable ratio between the real drug and the
dummy drug, according to the intervention protocol. Pa-
tients will be randomized to a high-dose group, low-
dose group or placebo control group, in which they will
take 6 g real drugs, 4 g real drugs + 2 g dummy drugs or
6 g dummy drugs, respectively. All drugs will be taken
orally with water before each meal three times a day for
8 weeks. A follow-up visit will be scheduled every
2 weeks after treatment. Patients who have not made a
full recovery from CNG after the clinical study will re-
ceive conventional treatment. Details of the procedures
and content are shown in Figure 2.Outcome measurement
Primary outcome
The eradication of epigastric pain is considered the primary
outcome to evaluate therapeutic effects. The visual analogue
scale (VAS) score (0 to 10 numeric pain intensity scale) for
epigastric pain was measured at every visit, ranging from 0
to 10, where a score of 0 suggests no epigastric pain and a
score of 10 indicates the most severe epigastric pain. The
eradication of epigastric pain is defined as a score of VAS
that stops rising after dropping to 0 during the study. The
eradication rate of epigastric pain will be compared among
the three groups, together with the change in VAS scores
before and after treatment in each group.Secondary outcomes
Endoscopic and histopathological examination The
change in red plaques, hemorrhagic spots/plaques, ero-
sion and bile reflux at endoscopy and the grade of active
chronic inflammation and chronic inflammation in the
gastric mucosa, depending on the histopathological
examination of biopsy specimens, will be compared
between visits one and six, according to the consensus
on CG in China.
Study period
allocation Post-allocation Close-out
Visit in doctor’s office Visit 1 Visit 2 Visit 3 Visit 4 Visit 5 Visit 6
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Drug recycling and count
Figure 2 Study schedule for patients.
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tion rate of HP after treatment will be used to evaluate
the effects of JWQTP.
The treatment efficacy in the Chinese medicine field
To evaluate the therapeutic effect in the CM field, the
TCM symptom score system (Table 3) will be used, follow-
ing the Guidelines for Clinical Research on Chinese New
Herbal Medicines (Trial Implementation). In the symptom
score system, the score of the primary symptom will
be based on the severity, duration and frequency ofthe symptoms. Secondary symptoms will be scored by
grading. The final point will be determined by the
sum of all symptom scores. The CM therapeutic
effect Index (CMTEI), as calculated with the following
formula, will be used to evaluate treatment efficacy in
the CM field.
CMTEI ¼
symptom score before treatment ‐ symptom score after treatment
symptom score before treatment
 
100%
Table 3 The traditional Chinese medicine (TCM) symptom score system for chronic non-atrophic gastritis (CNG)
Symptom Score Grading system
Primary symptom Epigastric pain Degree 0 score: None
2 score: Mild pain, does not affect work and life, VAS score 1 to 3
4 score: Moderate pain, affects work and life partly, VAS score 4 to 6
6 score: Severe pain, affects work and life fully, need rest, VAS score 7 to 10
Duration 0 score: None
2 score: Less than 1 hour a day
4 score: 1 to 2 hours a day
6 score: More than 2 hours a day
Total primary symptom scores Degree score + Duration score
Frequency of epigastric pain Score = the days of pain attack in a week (for example, a score of 7 indicates
pain everyday)
Secondary symptoms Weakness and lassitude 0 score: No
2 score: Yes
Dry mouth/bitter taste in mouth 0 score: No
2 score: Yes
Loss of appetite 0 score: None
1 score: food intake reduced by 1/3
2 score: food intake reduced by 1/3 to 2/3
3 score: food intake reduced by 2/3
Distention and fullness 0 score: None
1 score: Mild,
2 score: Moderate, does not affect work and life
3 score: Severe, need drug control
Loose stool 0 score: No
2 score: Yes
Belching 0 score: No
2 score: Yes
Total symptom score Total symptom score = total primary symptom scores + total secondary
symptom scores. Frequency of epigastric pain score is calculated
independently.
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lows: CMTEI ≥95% indicates clinical recovery; 95% >
CMTEI ≥70% indicates remarkable recovery; 70% >
CMTEI ≥30% indicates modest recovery; and CMTEI <
30% indicates inefficiency.
The change in the patient-reported outcome instrument for
chronic gastrointestinal diseases
Although the symptoms of chronic gastritis are not spe-
cific, the relief of clinical symptoms remains a major
therapeutic aim. The patient-reported outcome (PRO)
instrument for chronic gastrointestinal diseases (http://
www.proqolid.org/) [20], a 6-dimension, 35-item instru-
ment, will be performed on visits one and six, and the
results will be used to compare the two visits to assess any
changes in quality of life. The 35 items of the instrument
are the following: fatigue, disturbed sleep, no hungersensation, decreased appetite, afraid of society, dry mouth
or bitter taste in mouth, bad breath, pharyngeal foreign
body sensation, acid regurgitation, hiccup or belching,
nausea or vomiting, burning pain behind the sternum,
retrosternal pain, stomachache, gastric distension, gastric
discomfort, stomach burning, abdominal pain, abdominal
distension, degree of retrosternal pain, degree of heartburn,
degree of stomachache, degree of gastric distension, degree
of abdominal pain, degree of abdominal distension, diar-
rhea, constipation, incomplete sensation after defecation,
defecation urgency, weight loss, emotional fluctuation,
anxiety or nervous, worry about disease, impact on social
activities and impact on family status and function. All of
the items fall into five levels, which are scored as 0, 1, 2, 3
or 4, except for decreased appetite, which is grouped into
four levels and scored as 0, 1, 2 or 3. The final score will be
determined by the sum of all symptom scores.
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We will perform the following tests on all subjects to
screen for the JWQTP administration during the study:
physical examination (temperature, respiration, heart rate,
blood pressure, height and weight), complete blood cell
count, urinalysis, stool examination, fecal occult blood
test, liver function (ALT, AST, alkaline phosphatase (ALP),
serum total bilirubin (STB), and γ-glutamyl transpeptidase
(γ-GT)), renal function (Cr, micro albuminuria, serum
cystatin C, and urine N-acetyl-β-glucosaminidase) and
electrocardiogram (ECG) at the first, fourth and sixth
visits. In addition, a urine pregnancy test will be carried
out for female patients of childbearing age (Figure 2).
Data management
The completed CRFs will be submitted to the statistical
department after the inspections of the clinical investiga-
tors and trial inspectors for data entry and management.
All data will be entered twice electronically using the
EpiData3.1 database by two independent data managers
to ensure data accuracy. The investigators will resolve
any problems encountered by the data managers’ con-
cerning the data as soon as possible. Then, the data
managers will make corrections to the data, according to
the investigators’ instructions. A blind review will be
performed among the data managers, predominant in-
vestigator and sponsor to compile a report about the
quality of data management. The database will be locked
by the statistician, predominant investigator and sponsor
after the blind review and confirmation of database ac-
curacy. Then, the final trial dataset will be disclosed by
an independent assistant according to the randomization
list, where the data will be grouped into groups A, B or
C, and an independent statistician will make statistical
analysis using SAS 9.2 in a semi-blinded manner with
no suggestion of the exact treatment allocation. Finally,
the predominant investigator will write a conclusive re-
port of the statistical analysis in an unblinded manner.
Because there will be unified training prior to the study,
regular supervisor’s visits, data review by the clinical in-
vestigators, revisions by the data managers and a blind
review for the data after the study, no further data man-
agement committee will be set up to ensure the data’s
accuracy and validity. Only the clinical investigators and
trial inspector will have access to the medical records of
the subjects, and they will all sign a confidentiality agree-
ment. Anonymous data will be used for the inspection of
the pharmaceutical supervisory and administrative depart-
ment. Subjects’ medical records will be stored in the data
archive of the drug clinical trial agency after analysis.
Adverse event reporting
The safety of subjects is of paramount importance dur-
ing the study period, and every adverse event should bedocumented on the adverse event form (AEF) in great
detail. Adverse events (AEs) include any new diseases
and exacerbations of CNG or comorbidities related or
unrelated to the treatment. Any fatal, life-threatening,
disabling or event severe enough to warrant hospital ad-
mission or prolonged hospital stays occurring after any
dose of treatment pill and at any time during this study
should be considered an SAE. All of these data should be
recorded on an AEF with the corresponding treatment and
reported to the China Food and Drug Administration
(CFDA), provincial-level Food and Drug Administration,
sponsor and Independent Ethics Committee within 24 hours.
Then, the sponsor will inform the other four sites as soon as
possible. The severity of an AE is classified into three de-
grees: mild, moderate and severe. For the mild degree, a
small amount of indisposition arises, which the subject can
bear without any intervention and without influencing the
trial. For the moderate degree, a moderate amount of indis-
position develops, and some intervention should be taken to
get the trial going. For the severe degree, an enormous
amount of indisposition dictates that the subject should quit
the trial for his or her own safety. In the case of an SAE, the
investigator can break the blind to discover the subject’s
treatment allocation by reading the emergency letter corre-
sponding to the group allocation. Any AE related to the test
drug will be treated for free. On a separate note, any subject
with an intervention for AE must undertake a follow-up visit
within half a month for his or her health.
Sample size calculation
Based on the preliminary results of clinical research, no
less than an estimated 55% total efficiency will be ob-
tained with JWQTP treatment and approximately 30%
will be obtained with the intervention of a placebo. Using
a superiority test, no fewer than 66 subjects should be en-
rolled based on α = 0.05, β = 0.15 and power = 0.85 in each
treatment group. Allowing for a 20% drop-out, we there-
fore propose the recruitment of a total sample size of
240 patients, with average distributions among the
three groups.
Statistical analysis
A full analysis set (FAS) is the primary analysis popula-
tion for efficacy with an intention-to-treat principle. We
estimate the missing data using the last observation car-
ried forward (LOCF) method so that the population for
the final analysis corresponds with that at the beginning
of this study. The per-protocol set (PPS), in which all
subjects enable themselves to finish the study according
to the protocol, represents a subcardinal analysis popula-
tion for efficacy. Descriptive statistics will be presented
as the means, standard deviations, medians, minimum
values and maximum values for continuous variables and
as frequencies and percentages for categorical variables.
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will be used to compare baselines among patients, in-
cluding demographic data, vital signs, history of diseases,
basic treatment and so on. For the comparison of varia-
tions from the baseline to endpoint, Student’s t-test will
be performed on variables with normal distributions,
and the Wilcoxon rank sum test will be performed on
variables with non-normal distributions. The evaluation
of therapeutic effects will primarily be performed be-
tween baseline and visit six, in compliance with PPS, or
the time to withdraw from the study, in compliance with
FAS. In addition, the changes from baseline to visits two,
three, four or five will be evaluated. For continuous vari-
ables regarding therapeutic effect, an ANOVA will be
used for multiple comparisons of variation from baseline
among different groups, and Dunnett’s tests will be used
for comparisons within a group. A covariance analysis,
adjusted for the baseline covariate, will be used to evalu-
ate the differences of the symptom scores, VAS scores
and PRO instrument scores among the groups consider-
ing the center effect. The least square mean in each
group and the 95% confidence intervals of mean differ-
ences among groups will be calculated. The Cochran-
Mantel-Haenszel test, stratified by center effect, and the
logistic regression model, adjusted for covariates, will be
used on categorical variables in addition to the chi-
square test, Wilcoxon rank sum test or Fisher’s exact
test. The total drop-out rate in each group will be com-
pared with the drop-out rate due to AEs for drop-out
analyses using chi-square test or Fisher’s exact test. For
safety analyses, we will perform the chi-square test or
Fisher’s exact test to evaluate the incidence rate of AEs
among the groups and describe AEs using descriptive
statistics through listing.
All statistical tests will be performed by an independ-
ent statistician using SAS 9.2, assuming a two-sided test
and a 0.05 level of significance.
Discussion
To date, CNG remains unclear and has no specific rem-
edy. The presence or absence and severity of dyspepsia
have no obvious correlations with the histopathological
findings and endoscopic grading of CG [3]. The thera-
peutic aim of CNG is to ameliorate these symptoms and
to reduce the inflammation of the gastric mucosa, mainly
focusing on the eradication of HP, prokinetics, antacids
(H2-receptor antagonist or a proton pump inhibitor),
mucosal-protective agents, anti-depression drugs and
anti-anxiety drugs [5]. However, many CNG patients suf-
fer from recurrent bouts of dyspeptic symptoms because
these symptoms are easily influenced by psychological, so-
cial or dietary factors. TCM was more effective than
chemotherapy in the treatment of chronic gastritis, in-
cluding all subtypes, and no serious side effects have beenidentified. TCM has been widely considered an alternative
option for chronic gastritis in East Asia [7,21]. According
to the present findings, no scientifically rigorous trials
have been designed to treat CNG patients with SSQDDSS.
This study will be the first to explore the efficacy and
safety of JWQTP and to provide evidence and an optimal
dosage for a phase III clinical trial.
Trial status
This trial is preparing for recruitment of participants at
the time of manuscript submission.
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